A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients.
Phase 1
Recruiting
- Conditions
- PainOsteoarthritisChronic PainDorsal Root GanglionNav 1.7Post Herpetic NeuralgiaNeuropathic Pain
- Interventions
- Drug: iN1011-N17 HCl Capsule (Part 3)Drug: Placebo Capsule (Part 3)Drug: Placebo Capsule (Part 1)Drug: iN1011-N17 HCl Suspension (Part 1)Drug: iN1011-N17 HCl Capsule (Part 1)Drug: iN1011-N17 HCl Capsule (Part 2)Drug: iN1011-N17 Mesylate Capsule (Part 2)Drug: iN1011-N17 Mesylate Capsule (Part 3)
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- iN Therapeutics Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT06218784
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
Phase 1
Completed
- Conditions
- PainChronic PainPost Herpetic NeuralgiaOsteoarthritisNeuropathic PainNav 1.7
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- iN Therapeutics Co., Ltd.
- Target Recruit Count
- 104
- Registration Number
- NCT05496205
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
© Copyright 2025. All Rights Reserved by MedPath